Securities Fraud Investigation Into Marex Group plc (MRX) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MAREX GROUP PLC (MRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On August 5, 2025, NINGI Research published a report alleging, among other things, that Marex 'has engaged in a multi- year accounting scheme involving a web of opaque off-balance-sheet entities, fictitious intercompany transactions, and misleading disclosures to conceal significant losses, inflate profits, and mask its true risk exposure.' Specifically, the report states that the Company has concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund it both controls and trades with and that it is using the fund to generate non-cash trading profits and inflate operating cash flow by misclassifying structured note issuance as income.
On this news, Marex's stock price fell $2.33, or 6.2%, to close at $35.31 per share on August 5, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Marex should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Newmont (NEM) Surges 36% Over Last Quarter Following Strong Q2 2025 Earnings
Newmont recently announced its second quarter 2025 results, revealing a substantial increase in sales and net income compared to the prior year. The company also declared a quarterly dividend, authorized a significant share repurchase program, and completed a lease renewal in Ghana. Despite a decline in gold production, these developments likely bolstered investor confidence, contributing to the company's 36% share price increase over the last quarter. This upward movement aligns broadly with the market's positive trend, which included record highs in the Nasdaq and increased overall investor optimism amidst additional stock buyback activity and dividends within the sector. Every company has risks, and we've spotted 1 warning sign for Newmont you should know about. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. With Newmont's latest results showing a boost in sales and net income, the company's operational and strategic developments could reinforce its current narrative of resilience, focusing on gold demand and asset synergies. However, despite a recent uptick in its share price—36% this past quarter—the stock has achieved a total shareholder return of 63.75% over the past three years. This long-term performance reflects a complex mix of operational efficiency and market conditions, aligning with the company's efforts to maintain stability amidst fluctuating gold production rates. Over the last year, Newmont's performance has outpaced the broader US Metals and Mining industry, which returned 24.1%. This indicates a strong relative positioning, likely aided by the company's proactive engagement in shareholder returns through dividends and share repurchase programs. As for revenue and earnings forecasts, the recent lease renewal in Ghana and other long-term initiatives might offer sustained revenue support, though the decline in gold production introduces a risk to achieving the expected 1.6% annual revenue growth over the next three years. Currently trading at US$68.98, Newmont's share price aligns closely with the consensus price target of US$70.36, suggesting the market views the stock as fairly priced given current conditions. The modest price differential indicates skepticism about substantial immediate upside but acknowledges the potential for incremental value in alignment with forecasted earnings of US$6.3 billion by 2028. As such, the current developments signal a stable, though cautious, investor sentiment focused on sustainable growth. Unlock comprehensive insights into our analysis of Newmont stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NEM. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Where Will Walgreens Be in 1 Year?
Key Points Walgreens has agreed to be taken private for $11.45 per share. The deal has been approved by shareholders, and the stock is trading for slightly more than the takeover price. There's a nuance to the buyout story that could lead to an additional payout of as much as $3 per share. 10 stocks we like better than Walgreens Boots Alliance › Walgreens Boots Alliance (NASDAQ: WBA) has been a difficult stock to love for a few years, thanks to multiple corporate missteps. It got so bad that the board decided the best course of action was to effect a turnaround under private hands. That deal means that Walgreens won't be a publicly traded company a year from now. But that isn't the whole story, and more aggressive investors might still be interested in the stock because of a unique nuance of the take-private transaction. Here's what you need to know. From industry giant to going private There are only a handful of large pharmacy retailers, and Walgreens is one of them. For many years it was a growth business, but eventually the market became saturated. Often there was a Walgreens on one corner and one of its competitors just across the street. It's not shocking that growth stalled out throughout the sector. What happened next was that Walgreens looked for other ways to keep growing its business. It tried to buy into the pharmacy benefits management business, but that didn't go as well as hoped. And then it started to build out a healthcare clinic operation, but that didn't go as well as hoped. This company, which was on track to become a Dividend King, ended up cutting and then eliminating its dividend (the elimination came after the take-private agreement came about). Walgreens had recently been working to right-size its business, including closing locations. However, the revamp is likely to be a large undertaking that will be difficult to effect in the public markets. Investors don't like it when companies shrink, and that's exactly what Walgreens is in the process of doing. So, in early March, it agreed to be taken private by Sycamore Partners Management for $11.45 per share. The transaction is likely to close sometime in the second half of 2025. Why is Walgreens trading for more than the deal price? Normally in a takeover situation, the stock of the company being acquired trades for slightly less than the takeover price. That's because there is always a risk that the deal falls apart. However, Walgreens' shares are trading hands for slightly more than the takeover price, which suggests that there is something odd going on here. The wrinkle is that Sycamore Partners is planning on selling Walgreens' medical clinic business. And it will give Walgreens shareholders a chit that could be worth up to $3 per share, depending on the sales price it gets for the clinic business. So investors that are paying over $11.45 per share for Walgreens right now are, essentially, buying that chit, since they are locking in a loss on the Walgreens shares. There's just one problem. There is no timeline for the sale of the clinic business. And there is no guarantee on the price that Sycamore Partners will extract from the buyer. So the $3 chit could be worthless or, conversely, the length of time it takes to see any money could be very long, reducing the time value of the potential profit. There's just no way to tell what the outcome will be. And, as such, buying Walgreens today is not something that most investors should do, particularly if they are conservative by nature. More aggressive types that like special situations may like it, since the clinic business probably does have some value. But it is still a high-risk play that has a maximum upside of around 25%. That sounds like a lot, and it is, but only if the cash arrives quickly. Walgreens will be gone in a year, but not forgotten In one year, Walgreens will no longer be a public company. But it will linger in the minds of investors because of the $3 chit tied to the sale of the medical clinic business. That said, in the long term, it seems highly likely that Walgreens will eventually go public again -- with completely different shares -- hopefully with a better industry position. However, only aggressive investors should be looking at Walgreens right now. Should you buy stock in Walgreens Boots Alliance right now? Before you buy stock in Walgreens Boots Alliance, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Walgreens Boots Alliance wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Where Will Walgreens Be in 1 Year? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Can $10,000 in The Metals Company Stock Turn Into $50,000 by 2030?
Key Points TMC The Metals Company stock has been a huge winner in 2025, and its share price has more than quadrupled year to date. The company has seen huge gains as the importance of the the United States' domestic mineral sourcing capabilities has come into focus. TMC is a very risky investment, but there are realistic scenarios in which the stock could keep rocketing higher. 10 stocks we like better than TMC The Metals Company › TMC The Metals Company (NASDAQ: TMC) has been one of the market's most explosive stocks across 2025's trading. Even after a recent pullback, the company's share price has surged roughly 368% year to date as of this writing. TMC's huge gains have been powered by expectations that regulatory shifts and other political dynamics will fast-track the seabed mining specialist's path to operational deployment and rapid growth. If you're wondering whether the mining company has what it takes to turn a $10,000 investment into $50,000 or more over the next five years, read on for a look at key dynamics that could shape the stock's performance over that time frame. Could TMC 5x over the next five years? TMC's business is still in a pre-revenue state, and its stock is a risky investment candidate. On the other hand, some key dynamics have been moving in the company's favor -- and there are feasible outcomes that could result in its share price surging far above current levels. President Donald Trump signed an executive order in April to expedite permitting applications for seabed mining operations, and TMC responded by submitting several applications for regulatory approvals. Seabed mining capabilities could be crucial to helping to improve the United States' ability to source rare earth minerals domestically. Along those lines, the recent pullback for TMC stock has actually been driven by signs suggesting that the Trump administration could reach a trade agreement with China that secures future access to Chinese minerals. With a market capitalization of roughly $1.9 billion, TMC is still a relatively small company. Its stock is also a highly speculative investment play. While the company's shares come with a very high level of investment risk, I think there's actually a very good chance that its valuation will bound well above current levels. Whether or not the company's stock can deliver 5x returns over the next five years remains to be seen, but geopolitical dynamics and the importance of rare earth mineral sourcing suggest the potential is there even if that outcome is far from a safe bet. Should you buy stock in TMC The Metals Company right now? Before you buy stock in TMC The Metals Company, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TMC The Metals Company wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Can $10,000 in The Metals Company Stock Turn Into $50,000 by 2030? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
